ŠUSTKOVÁ, Zuzana, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ and Jiří MAYER. How to select older patients with acute myeloid leukemia fit for intensive treatment? Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2021, vol. 39, No 2, p. 151-161. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2798.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name How to select older patients with acute myeloid leukemia fit for intensive treatment?
Authors ŠUSTKOVÁ, Zuzana (203 Czech Republic, guarantor), Lukáš SEMERÁD (203 Czech Republic), Barbora WEINBERGEROVÁ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2021, 0278-0232.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.850
RIV identification code RIV/00216224:14110/21:00120701
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/hon.2798
UT WoS 000566365200001
Keywords in English AML; elderly; geriatric assessment; negative prognostic factors; older patients
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 08:34.
Abstract
Outcomes of the treatment of older patients with acute myeloid leukemia (AML) are unsatisfactory due to a higher incidence of negative patient- and disease-related risk factors connected with aging. Prediction of poor tolerance to aggressive treatment and low response to standard intensive chemotherapy are the main root causes why the treatment decision is challenging. For a long time, negative prognostic factors for treatment outcomes, overall survival, and early death such as the age itself, low-performance status, high-comorbidity burden, adverse cytogenetics, and secondary AML have been known, and they are routinely taken into account during therapeutic balance. In consideration of the risk factors and specific laboratory results, prognostic models have been created. Despite the abovementioned facts, the survival of older patients with AML remains very poor, that holds true even for the intensive therapy. For that reason, there is an increased effort to find a better approach how to select patients who would benefit from intensive treatment without decreasing their quality of life through severe complications with risk of high treatment-related mortality. Based on the results of clinical studies, the geriatric assessment could be the missing step which would help select older patients who are really fit for intensive treatment and who will benefit from it the most. This review focuses on the risk factors that should be taken under advisement when the decision about the treatment is made. With reference to the published information, we propose an algorithm how to identify fit, vulnerable, and frail patients.
PrintDisplayed: 22/6/2024 13:59